PIK3CA and breast carcinoma: These data coupled with the recent clinical data emerging around p110α-selective molecules in ER+/HER2− breast cancer indicate that exploring PI3K inhibition as a means to overcome and/or prevent resistance to CDK4/6-based therapies could be a very attractive approach that might be fast-tracked towards clinical translation.